Related Articles
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
NRAS and BRAF mutation frequency in primary oral mucosal melanoma
Molecular alterations in clinical stageĀ III cutaneous melanoma: Correlation with clinicopathological features and patient outcome
Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma